These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 37084751)

  • 1. SARS-CoV-2 incubation period across variants of concern, individual factors, and circumstances of infection in France: a case series analysis from the ComCor study.
    Galmiche S; Cortier T; Charmet T; Schaeffer L; Chény O; von Platen C; Lévy A; Martin S; Omar F; David C; Mailles A; Carrat F; Cauchemez S; Fontanet A
    Lancet Microbe; 2023 Jun; 4(6):e409-e417. PubMed ID: 37084751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing changes in incubation period, serial interval, and generation time of SARS-CoV-2 variants of concern: a systematic review and meta-analysis.
    Xu X; Wu Y; Kummer AG; Zhao Y; Hu Z; Wang Y; Liu H; Ajelli M; Yu H
    BMC Med; 2023 Sep; 21(1):374. PubMed ID: 37775772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral kinetics of SARS-CoV-2 following onset of COVID-19 in symptomatic patients infected with the ancestral strain and omicron BA.2 in Hong Kong: a retrospective observational study.
    Lin Y; Wu P; Tsang TK; Wong JY; Lau EHY; Yang B; Leung GM; Cowling BJ
    Lancet Microbe; 2023 Sep; 4(9):e722-e731. PubMed ID: 37659420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 rapid antigen test sensitivity and viral load in newly symptomatic hospital employees in Berlin, Germany, December, 2020 to February, 2022: an observational study.
    Meiners L; Horn J; Jones TC; Mühlemann B; Schmidt ML; Walper F; Menzel P; Schwarzer R; Rose R; Krumbholz A; Corman VM; Seybold J; Drosten C
    Lancet Microbe; 2024 Jun; 5(6):e538-e546. PubMed ID: 38759669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of antigen lateral flow devices in the UK during the alpha, delta, and omicron waves of the SARS-CoV-2 pandemic: a diagnostic and observational study.
    Eyre DW; Futschik M; Tunkel S; Wei J; Cole-Hamilton J; Saquib R; Germanacos N; Dodgson AR; Klapper PE; Sudhanva M; Kenny C; Marks P; Blandford E; Hopkins S; Peto TEA; Fowler T
    Lancet Infect Dis; 2023 Aug; 23(8):922-932. PubMed ID: 37001541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Replacement dynamics and the pathogenesis of the Alpha, Delta and Omicron variants of SARS-CoV-2.
    Ward T; Glaser A; Overton CE; Carpenter B; Gent N; Seale AC
    Epidemiol Infect; 2022 Dec; 151():e32. PubMed ID: 36535802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incubation Period of COVID-19 Caused by Unique SARS-CoV-2 Strains: A Systematic Review and Meta-analysis.
    Wu Y; Kang L; Guo Z; Liu J; Liu M; Liang W
    JAMA Netw Open; 2022 Aug; 5(8):e2228008. PubMed ID: 35994285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the incubation period, serial interval, and infectiousness profile between SARS-CoV-2 Omicron and Delta variants.
    Guo Z; Zhao S; Mok CKP; So RTY; Yam CHK; Chow TY; Chan TCP; Wei Y; Jia KM; Wang MH; Chong KC; Yeoh EK
    J Med Virol; 2023 Mar; 95(3):e28648. PubMed ID: 36892159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study.
    Menni C; Valdes AM; Polidori L; Antonelli M; Penamakuri S; Nogal A; Louca P; May A; Figueiredo JC; Hu C; Molteni E; Canas L; Österdahl MF; Modat M; Sudre CH; Fox B; Hammers A; Wolf J; Capdevila J; Chan AT; David SP; Steves CJ; Ourselin S; Spector TD
    Lancet; 2022 Apr; 399(10335):1618-1624. PubMed ID: 35397851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Association Between Clinical Severity and Incubation Period of SARS-CoV-2 Delta Variants: Retrospective Observational Study.
    Wang K; Luan Z; Guo Z; Ran J; Tian M; Zhao S
    JMIR Public Health Surveill; 2022 Nov; 8(11):e40751. PubMed ID: 36346940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shorter Incubation Period among COVID-19 Cases with the BA.1 Omicron Variant.
    Tanaka H; Ogata T; Shibata T; Nagai H; Takahashi Y; Kinoshita M; Matsubayashi K; Hattori S; Taniguchi C
    Int J Environ Res Public Health; 2022 May; 19(10):. PubMed ID: 35627870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
    Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
    JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of 2 Rapid Antigen Tests During 3 Phases of SARS-CoV-2 Variants.
    Drain PK; Bemer M; Morton JF; Dalmat R; Abdille H; Thomas KK; Uppal TK; Hau D; Green HR; Gates-Hollingsworth MA; AuCoin DP; Verma SC
    JAMA Netw Open; 2022 Aug; 5(8):e2228143. PubMed ID: 36001317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transmission Characteristics and Inactivated Vaccine Effectiveness Against Transmission of SARS-CoV-2 Omicron BA.5 Variants in Urumqi, China.
    Wang K; Guo Z; Zeng T; Sun S; Lu Y; Wang J; Li S; Luan Z; Li H; Zhang J; Wang Y; Lu Y; Zhao S
    JAMA Netw Open; 2023 Mar; 6(3):e235755. PubMed ID: 36995713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance.
    Britton A; Fleming-Dutra KE; Shang N; Smith ZR; Dorji T; Derado G; Accorsi EK; Ajani UA; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Mar; 327(11):1032-1041. PubMed ID: 35157002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.
    Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
    PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.